According to research by nova one advisor, the global cell and gene therapy market size was valued at $18.13 billion in 2023 ...

PHC Corporation and CCRM have signed a Master Collaboration Agreement to collaborate on developing primary T-cell expansion ...

The company signed the agreement with Karolinska Institutet's Department of Cell and Molecular Biology professor Johan ...

Cellistic, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing services, announces the launch of ...

TG Therapeutics will use MaxCyte’s technology to advance toward a clinical trial its azer-cel CAR T-cell therapy for ...

PHC and CCRM collaborate to develop primary T-cell expansion culture processes to enhance efficiency and improve cell quality: Tokyo, Japan Tuesday, February 11, 2025, 14:00 Hrs [ ...

PHC Corporation has signed a Master Collaboration Agreement with CCRM to work together on the development of primary T-cell(*1) expansion culture ...

These innovations are reducing manufacturing time, improving cell persistence, and increasing therapeutic efficacy. Additionally, the emergence of dual-targeting CARs and next-generation T-cell ...

Cell and gene therapies can be life-changing for patients with certain conditions, but the process of receiving them poses barriers for patients and caregivers that require multistakeholder solutions, ...

NEW YORK – Galapagos said on Monday that it has partnered with NecstGen, a contract development and manufacturing organization (CDMO), to support decentralized manufacturing of Galapagos' cell therapy ...